Home » Stocks » IKT

Inhibikase Therapeutics, Inc. (IKT)

Stock Price: $5.49 USD 0.36 (7.02%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 45.09M
Revenue (ttm) 698,468
Net Income (ttm) -2.85M
Shares Out 8.21M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.49
Previous Close $5.13
Change ($) 0.36
Change (%) 7.02%
Day's Open 5.14
Day's Range 5.14 - 5.85
Day's Volume 39,778
52-Week Range 5.00 - 11.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ATLANTA, April 21, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's dise...

2 weeks ago - PRNewsWire

ATLANTA, April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease (PD) and r...

1 month ago - PRNewsWire

ATLANTA, Feb. 22, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disor...

2 months ago - PRNewsWire

ATLANTA--(BUSINESS WIRE)--Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and relate...

2 months ago - Business Wire

ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disord...

4 months ago - PRNewsWire

ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related dis...

4 months ago - PRNewsWire

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related...

4 months ago - PRNewswire

Eight SPACs went public this past week but no IPOs, as all three scheduled deals postponed or withdrew. New filing activity picked up, led by long-awaited delivery service unicorn DoorDash (DASH), and s...

5 months ago - NASDAQ

Inhibikase Therapeutics, a clinical stage biotech developing kinase inhibitors for Parkinson's and related disorders, lowered the proposed deal size for its upcoming IPO on Tuesday. The Atlanta, GA-base...

6 months ago - NASDAQ

Inhibikase Files Registration Statement for Proposed Initial Public Offering - read this article along with other careers information, tips and advice on BioSpace

9 months ago - BioSpace

About IKT

Inhibikase Therapeutics is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. We filed two Investigational New Drug, or IND, applications with the U.S. Food and Drug Administration, or FDA, in the first quarter of 2019 for our lead asset candidate, IkT-148009. One IND is for the treatment of Parkinson’s Disease, while the second is for treatment of gastrointestinal, or GI, complications that arise as early symptoms of PD in patient... [Read more...]

Industry
Biotechnology
IPO Date
Dec 23, 2020
CEO
Milton H. Werner
Employees
3
Stock Exchange
NASDAQ
Ticker Symbol
IKT
Full Company Profile

Financial Performance

In 2020, IKT's revenue was $698,468, a decrease of -37.79% compared to the previous year's $1.12 million. Losses were -$2.85 million, -50.24% less than in 2019.

Financial Statements